Benzene

Benzene

SCHEMBL2344334

NS(=O)(=O)O.c1ccccc1

nearest known ligand 0.73

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 11/20 0.73
CA2 P00918 10/20 0.73
CA9 Q16790 8/20 0.73
CA5A P35218 6/20 0.73
CA5B Q9Y2D0 5/20 0.73
CA6 P23280 4/20 0.73
CA7 P43166 4/20 0.73
TSHR P16473 4/20 0.73
CA4 P22748 3/20 0.73
NT5E P21589 1/20 0.73
CA12 O43570 4/20 0.42
CA3 P07451 2/20 0.42
CA14 Q9ULX7 2/20 0.42
PLA2G7 Q13093 1/20 0.42
CA13 Q8N1Q1 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
TDP1 Q9NUW8 1/20 0.36
KDM4E B2RXH2 3/20 0.35
BLM P54132 2/20 0.35
MAPT P10636 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzene SCHEMBL27543069 0.96 CA1 (0.67) CA1CA2CA9CA5ACA5B
Sulfamate SCHEMBL2545884 0.85 CA1 (1.00) CA1CA2CA9CA5ACA5B
Sulfamate SCHEMBL11400 0.85
Sulfamate SCHEMBL285371 0.85
Benzene SCHEMBL27613221 0.84 CA1 (0.50) CA1CA2CA9CA5ACA5B
Sulfamate SCHEMBL27301417 0.82 CA1 (0.73) CA1CA2CA9CA5ACA5B
Sulfamate SCHEMBL5187482 0.82
Sulfamate SCHEMBL23581784 0.80
Sulfamate SCHEMBL20874504 0.80
Sulfamate SCHEMBL11115704 0.80

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117264175-A Polyisocyanate composition, aqueous coating composition, coated substrate, and method for producing polyisocyanate composition 旭化成株式会社 2023-12-22 CN disclosed
CN-117229476-A Polyisocyanate composition, blocked polyisocyanate composition, polyurethane resin composition, coating composition, and coated substrate 旭化成株式会社 2023-12-15 CN disclosed
US-20230265087-A1 SMALL MOLECULE ACTIVATORS OF TIE-2 EyePoint, Inc. 2023-08-24 US disclosed
US-11613534-B2 Small molecule activators of Tie-2 EyePoint Pharmaceuticals, Inc. (US) 2023-03-28 US disclosed
US-20210353568-A1 DERMATOLOGIC TOPICAL APPLICATIONS OF ROR GAMMA AND ROR GAMMA-T INHIBITORS FOR THE PREVENTION OF SKIN CANCER DEVELOPMENT YALE UNIVERSITY (US) 2021-11-18 US disclosed
US-20210147404-A1 SMALL MOLECULE ACTIVATORS OF TIE-2 EyePoint, Inc. 2021-05-20 US disclosed
WO-2021086904-A1 SMALL MOLECULE ACTIVATORS OF TIE-2 Aerpio Pharmaceuticals, Inc. (US) 2021-05-06 WO disclosed
WO-2020061024-A1 DERMATOLOGIC TOPICAL APPLICATIONS OF ROR GAMMA AND ROR GAMMA-T INHIBITORS FOR THE PREVENTION OF SKIN CANCER DEVELOPMENT YALE UNIVERSITY (US) 2020-03-26 WO disclosed
CN-104428292-B Phenylalkyl sulfamate compound and muscle relaxant composition comprising same 生物药品解决方案有限公司 2017-02-08 CN disclosed
EP-2584399-B1 TRANSFLECTIVE LIQUID-CRYSTAL DISPLAY DEVICE TOPPAN PRINTING CO LTD (JP) 2016-02-24 EP disclosed
CN-100366685-C Water-base black ink composition and colored material NIPPON KAYAKU KK (JP) 2008-02-06 CN disclosed
CN-101054352-A New strontium salts of sulphonic acids, a process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2007-10-17 CN disclosed
CN-1981004-A Inkjet black ink, ink set, inkjet recording method, ink cartridge, recording unit, and inkjet recorder CANON KK (JP) 2007-06-13 CN disclosed
CN-1756812-A aqueous black ink composition and colored article NIPPON KAYAKU KK (JP) 2006-04-05 CN disclosed
US-20050196658-A1 proton-conducting electrolyte that has excellent proton-conducting properties, heat resistance, and chemical stability without containing any fluorine. The proton-conducting electrolyte contains polyamide sulfamidic acid in which a polyamide backbone has side chains of sulfamidic acid groups SAMSUNG SDI CO., LTD. (KR) 2005-09-08 US disclosed
US-6369092-B1 Method for treating neoplasia by exposure to substituted benzimidazole derivatives CELL PATHWAYS, INC. 2002-04-09 US disclosed
US-5464731-A HAVING IMPROVED BACKGROUND AND GRADATION FUJI PHOTO FILM CO., LTD. (JP) 1995-11-07 US disclosed
EP-0467710-A2 Method for treating Parkinson's disease employing the ATP-sensitive potassium channel blocker quinine E.R. SQUIBB & SONS, INC. (US) 1992-01-22 EP disclosed
US-4714700-A TRANQUILIZERS, ANXIOLYTIC AGENTS CHOAY S.A. (FR) 1987-12-22 US disclosed
US-4567134-A NO WATER WASHING AFTER FIXING KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) 1986-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210147404-A1 SMALL MOLECULE ACTIVATORS OF TIE-2 TIE1, TEK, KDR CA1 4801/4885CA2 3100/4885CA9 4662/4885
US-11613534-B2 Small molecule activators of Tie-2 TIE1, TEK, KDR CA1 4801/4885CA2 3100/4885CA9 4662/4885
US-20230265087-A1 SMALL MOLECULE ACTIVATORS OF TIE-2 TIE1, TEK, KDR CA1 4801/4885CA2 3100/4885CA9 4662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.